Top

Published in:

01-06-2019 | Glioma | Laboratory Investigation

Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas

Authors: Chongxian Hou, Shigeru Yamaguchi, Yukitomo Ishi, Shunsuke Terasaka, Hiroyuki Kobayashi, Hiroaki Motegi, Kanako C. Hatanaka, Kiyohiro Houkin

Published in: Journal of Neuro-Oncology | Issue 2/2019

Abstract

Purpose

5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) appears to be a promising treatment for glioma. However, 5-ALA-mediated fluorescence cannot always be detected in grade II/III gliomas. We hypothesized that gene expression patterns in the Protoporphyrin IX (PpIX) synthesis pathway may be associated with intraoperative fluorescence status of grade II/III gliomas, and then attempted to identify the key molecule of 5-ALA-mediated fluorescence.

Methods

Using 50 surgically obtained specimens, which were diagnosed as grade II and III gliomas, we analyzed gene expression within the PpIX synthesis pathway to identify candidate molecules according to intraoperative 5-ALA-mediated fluorescence status. The most likely candidate gene was selected and confirmed by protein expression analysis. To evaluate the biological function of the molecule in PpIX synthesis, functional analysis was performed using specific, small interference (si)RNA in the SW-1783 human grade III glioma cell line.

Results

Among the genes involved in the porphyrin synthesis pathway, the mRNA expression of Peptide transporter 2 (PEPT2) in FGS fluorescence-positive gliomas was significantly higher than that in fluorescence-negative gliomas. Protein expression of PEPT2 was also significantly higher in the fluorescence-positive gliomas, which was confirmed by western blot analysis and immunofluorescence analysis. The siRNA-mediated downregulation of the mRNA and protein expression of PEPT2 led to decreased PpIX fluorescence intensity, as confirmed by fluorescence spectrum analysis.

Conclusions

The results suggest PEPT2 is an important candidate molecule in 5-ALA-mediated FGS in grade II/III gliomas. As the overexpression of PEPT2 was associated with higher PpIX fluorescence intensity, PEPT2 may improve fluorescence-guided resection in grade II/III gliomas.

Available only for authorised users

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRef

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190 CrossRefPubMed

Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–764. https://doi.org/10.1227/01.neu.0000318159.21731.cf discussion 264–756 CrossRefPubMed

Aydin H, Sillenberg I, von Lieven H (2001) Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 177:424–431CrossRefPubMed

Clarke J, Butowski N, Chang S (2010) Recent advances in therapy for glioblastoma. Arch Neurol 67:279–283. https://doi.org/10.1001/archneurol.2010.5 CrossRefPubMed

Theeler BJ, Groves MD (2011) High-grade gliomas. Curr Treat Options Neurol 13:386–399. https://doi.org/10.1007/s11940-011-0130-0 CrossRefPubMed

Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409CrossRefPubMed

Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, Diez-Valle R (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 72:915–920. https://doi.org/10.1227/neu.0b013e31828c3974 discussion 920–911 CrossRefPubMed

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9 CrossRefPubMed

10.

Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518–525 discussion 525–516 CrossRefPubMed

11.

Utsuki S, Oka H, Sato S, Suzuki S, Shimizu S, Tanaka S, Fujii K (2006) Possibility of using laser spectroscopy for the intraoperative detection of nonfluorescing brain tumors and the boundaries of brain tumor infiltrates. Technical note. J Neurosurg 104:618–620. https://doi.org/10.3171/jns.2006.104.4.618 CrossRefPubMed

12.

Jaber M, Wolfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, Zoubi T, Weckesser M, Stummer W (2016) The Value of 5-Aminolevulinic acid in low-grade gliomas and high-grade gliomas lacking glioblastoma imaging features: an analysis based on fluorescence, magnetic resonance imaging, 18F-fluoroethyl tyrosine positron emission tomography, and tumor molecular factors. Neurosurgery 78:401–411. https://doi.org/10.1227/neu.0000000000001020 CrossRefPubMed

13.

Chen X, Keep RF, Liang Y, Zhu HJ, Hammarlund-Udenaes M, Hu Y, Smith DE (2017) Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: a microdialysis study. Biochem Pharmacol 131:89–97. https://doi.org/10.1016/j.bcp.2017.02.005 CrossRefPubMedPubMedCentral

14.

Hu Y, Ocheltree SM, Xiang J, Keep RF, Smith DE (2005) Glycyl-l-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2. Pharm Res 22:1281–1286. https://doi.org/10.1007/s11095-005-5261-0 CrossRefPubMed

15.

Novotny A, Xiang J, Stummer W, Teuscher NS, Smith DE, Keep RF (2000) Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J Neurochem 75:321–328CrossRefPubMed

16.

Daniel H, Kottra G (2004) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447:610–618. https://doi.org/10.1007/s00424-003-1101-4 CrossRefPubMed

17.

Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, Leibach FH (1995) Molecular cloning of PEPT 2, a new member of the H +/peptide cotransporter family, from human kidney. Biochem Biophys Acta 1235:461–466CrossRefPubMed

18.

Rubio-Aliaga I, Daniel H (2002) Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci 23:434–440CrossRefPubMed

19.

Terada T, Inui K (2004) Peptide transporters: structure, function, regulation and application for drug delivery. Curr Drug Metab 5:85–94CrossRefPubMed

20.

Terada T, Saito H, Sawada K, Hashimoto Y, Inui K (2000) N-terminal halves of rat H +/peptide transporters are responsible for their substrate recognition. Pharm Res 17:15–20CrossRefPubMed

21.

Doring F, Walter J, Will J, Focking M, Boll M, Amasheh S, Clauss W, Daniel H (1998) Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Investig 101:2761–2767. https://doi.org/10.1172/JCI1909 CrossRefPubMed

22.

Wang M, Zhang X, Zhao H, Wang Q, Pan Y (2010) Comparative analysis of vertebrate PEPT1 and PEPT2 genes. Genetica 138:587–599. https://doi.org/10.1007/s10709-009-9431-6 CrossRefPubMed

23.

Verrey F, Singer D, Ramadan T, Vuille-dit-Bille RN, Mariotta L, Camargo SM (2009) Kidney amino acid transport. Pflugers Arch 458:53–60. https://doi.org/10.1007/s00424-009-0638-2 CrossRefPubMed

24.

Sala-Rabanal M, Loo DD, Hirayama BA, Wright EM (2008) Molecular mechanism of dipeptide and drug transport by the human renal H +/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol 294:F1422–1432. https://doi.org/10.1152/ajprenal.00030.2008 CrossRefPubMed

25.

Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209–1216. https://doi.org/10.1124/dmd.107.015263 CrossRefPubMed

26.

Groneberg DA, Nickolaus M, Springer J, Doring F, Daniel H, Fischer A (2001) Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake. Am J Pathol 158:707–714. https://doi.org/10.1016/S0002-9440(10)64013-8 CrossRefPubMedPubMedCentral

27.

Gukasyan HJ, Uchiyama T, Kim KJ, Ehrhardt C, Wu SK, Borok Z, Crandall ED, Lee VHL (2017) Oligopeptide transport in rat lung alveolar epithelial cells is mediated by Pept2. Pharm Res 34:2488–2497. https://doi.org/10.1007/s11095-017-2234-z CrossRefPubMed

28.

Frey IM, Rubio-Aliaga I, Klempt M, Wolf E, Daniel H (2006) Phenotype analysis of mice deficient in the peptide transporter PEPT2 in response to alterations in dietary protein intake. Pflugers Arch 452:300–306. https://doi.org/10.1007/s00424-005-0042-5 CrossRefPubMed

29.

Rubio-Aliaga I, Frey I, Boll M, Groneberg DA, Eichinger HM, Balling R, Daniel H (2003) Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol Cell Biol 23:3247–3252CrossRefPubMedPubMedCentral

30.

Zhao SG, Chen XF, Wang LG, Yang G, Han DY, Teng L, Yang MC, Wang DY, Shi C, Liu YH, Zheng BJ, Shi CB, Gao X, Rainov NG (2013) Increased expression of ABCB6 enhances protoporphyrin IX accumulation and photodynamic effect in human glioma. Ann Surg Oncol 20:4379–4388. https://doi.org/10.1245/s10434-011-2201-6 CrossRefPubMed

31.

Takahashi K, Ikeda N, Nonoguchi N, Kajimoto Y, Miyatake S, Hagiya Y, Ogura S, Nakagawa H, Ishikawa T, Kuroiwa T (2011) Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence. Neuro-Oncology 13:1234–1243. https://doi.org/10.1093/neuonc/nor116 CrossRefPubMedPubMedCentral

32.

Hu Y, Shen H, Keep RF, Smith DE (2007) Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103:2058–2065. https://doi.org/10.1111/j.1471-4159.2007.04905.x CrossRefPubMed

Title: Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas
Authors: Chongxian Hou
Shigeru Yamaguchi
Yukitomo Ishi
Shunsuke Terasaka
Hiroyuki Kobayashi
Hiroaki Motegi
Kanako C. Hatanaka
Kiyohiro Houkin
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Glioma
Glioma
Glioma
Published in: Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03158-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

Rap2B promotes cell adhesion, proliferation, migration and invasion of human glioma

Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells

Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis

Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours